CLAIMS

1. Alisporivir for use in treatment of a Hepatitis C virus genotype 1 infected patient in combination with standard of care characterized in that

(i) the patient is a relapser or a non-responder patient, and

(ii) alisporivir is administered during an initial phase in an amount of about 600 mg, twice per day; followed by administering alisporivir during a second phase in an amount of about 600 to about 1000 mg once per day.

2. Alisporivir for use according to claim 1 characterized in that alisporivir is administered during an initial phase in an amount of about 600 mg, twice per day for 7 days; followed by administering alisporivir during a second phase in an amount of about 600 or about 1000 mg or 800 mg once per day for up to 23, 47 or 71 weeks.

3. Alisporivir for use according to claim 2 characterized in that alisporivir is administered during an initial phase in an amount of about 600 mg, twice per day for 7 days; followed by administering alisporivir during a second phase in an amount of 600 mg once per day for up to 47 weeks.

4. Alisporivir for use according to claim 1, wherein the standard of care is a combination of interferon with ribavirin.

5. Alisporivir for use according to claim 4, wherein said interferon is pegylated interferon alpha-2a, and is administered in an amount of 180 micrograms once per week.

6. Alisporivir for use according to claim 4, wherein said ribavirin is administered at between 1000 mg to 1200 mg per day.

7. A method of treating of a Hepatitis C virus genotype 1 infected relapser or non-responder patient with alisporivir in combination with standard of care, the method comprising administering alisporivir during an initial phase in an amount of about 600 mg, twice per day for 7 days; followed by administering alisporivir during a second phase in an amount of about 600 to about 1000 mg once per day for up to 23, 47 or 71 weeks.

8. Use of alisporivir in the manufacture of a medicament for treatment of a Hepatitis C virus genotype 1 infected patient characterized in that

(i) the patient is a relapser or a non-responder patient and

(ii) alisporivir is administered during an initial phase in an amount of about 600 mg, twice per day for7 days; followed by administering alisporivir during a second phase in an amount of about 600 to about 800 mg once per day for up to 23, 47 or 71 weeks

and wherein alisporivir is administered in combination with standard of care throughout the initial and second phases.

9. A combination of alisporivir, and standard of care for use in treatment of a Hepatitis C virus genotype 1 infected relapser or non-responder patient characterized in that alisporivir is administered during an initial phase in an amount of about 600 mg, twice per day for7 days; followed by administering alisporivir during a second phase in an amount of about 600 to about 800 mg once per day for up to 23, 47 or 71 weeks.

10. A therapeutic regimen comprising administering alisporivir during an initial phase in an amount of about 600 mg, twice per day for 7 days; followed by administering alisporivir during a second phase in an amount of about 600 to about 800 mg once per day for up to 23, 47 or 71 weeks and wherein alisporivir is administered in combination with standard of care throughout the initial and second phases.

11. A pharmaceutical composition comprising alisporivir for use according to claim 1.

12. A package comprising the pharmaceutical composition according to claim 11 in combination with instructions to administer said composition.

Claims

1. An invention not claimed in any divisional application.